The move comes less than three years after the Gaithersburg biotech spun out of MedImmune.
Image: Viela Bio CEO Bing Yao, pictured here on the company's IPO day at the Nasdaq. LIBBY GREENE
SUBSCRIBE
Biohealth Innovation
Founding Member of
